Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Long COVID Syndrome
NCT06907251Phase 3Not yet recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Dec 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in long COVID syndrome (PASC) (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: EQ-5D derived utility score at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
long COVID syndrome (PASC)
Beyond the preview
Go deeper on NCT06907251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907251.